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Abstract 
The term third-wave cognitive behavioural therapy (CBT) encompasses new forms 
of CBT that both extend and innovate within CBT. Most third-wave therapies have been 
subject to RCTs focused on clinical effectiveness, however the number and quality of 
economic evaluations in these RCTs has been unknown and may be few. Evidence about 
efficiency of these therapies may help support decisions on efficient allocation of resources 
in health policies. The main aim of this study was to systematically review the economic 
impact of third-wave therapies in the treatment of patients with physical or mental 
conditions. We conducted a systematic literature search in PubMed, PsycINFO, EMBASE, 
and CINALH to identify economic evaluations of third-wave therapies. Quality and Risk 
of Bias (RoB) assessment of economic evaluations was also made using the Drummond 
35-item checklist and the Cochrane Collaboration’s tool for assessing risk of bias, 
respectively. Eleven RCTs were included in this systematic review. Mindfulness-Based 
Cognitive Therapy (MBCT), Mindfulness-Based Stress Reduction (MBSR), Acceptance 
and Commitment Therapy (ACT), Dialectical Behavior Therapy (DBT), and extended 
Behaviour Activation (eBA) showed acceptable cost-effectiveness and cost-utility ratios. 
No study employed a time horizon of more than 3 years. Quality and RoB assessments 
highlight some limitations that temper the findings. There is some evidence that MBCT, 
MBSR, ACT, DBT, and eBA are efficient from a societal or a third-party payer 
perspective. No economic analysis was found for many third-wave therapies. Therefore, 
more economic evaluations with high methodological quality are needed. 
 
Keywords: Third-wave cognitive behavioural therapies; Mindfulness; Acceptance; 
Economic evaluation; Systematic review 
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Introduction 
Description of third-wave therapies 
According to Hayes (2004a), the first- and second-wave forms of cognitive 
behaviour therapy (CBT) emerged as attempts to develop well-specified and rigorous 
applied techniques based on empirically validated basic principles. Unlike earlier 
approaches, CBT is focused directly on symptom relief or behavior change. The “first 
wave” of CBT, also simply called behavior therapy, was developed in the 1950s, aimed to 
do this predominantly through the application of principles of classical and operant 
conditioning (Hayes, 2004a). However, stimulus–response associationism and behavior 
analysis appeared inadequate to address the role of human language and cognition in 
complex behavior patterns, and a need for both principles and methods that could 
incorporate patients’ thoughts and feelings was clear (Hayes, 2016; Kahl, Winter & 
Schweiger,2012). Thus, second-wave forms of CBT emerged in the 1960s with a focus on 
assessing and intervening in relation to dysfunctional cognitions. Within these approaches 
negative thoughts and irrational beliefs are identified, challenged and disputed by means of 
techniques such as cognitive restructuring, in which the therapist and patient work together 
to change maladaptive thinking patterns, encouraging patients to replace these with more 
rational, realistic ones (e.g. Beck, 1967). From the 1960s until present, second wave forms 
of CBT, have been the dominant psychotherapies worldwide and are demonstrated to be 
cost-effective for a wide range of disorders (Mavranezouli et al., 2015; Pompoli et al., 
2016; Skapinakis et al., 2016). 
Second-wave CBT has succeeded in many respects, but has not been exempt from 
criticism (Hayes 2004a). First, effect sizes for CBT for some conditions are only modest, 
suggesting either weakness in the underlying model or some limits in application (e.g., 
Cuijpers et al., 2013). Second, hypothesised cognitive mediators frequently fail to explain 
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the results of CBT, casting doubt on the intended aims of conventional cognitive therapy 
methods (David & Montgomery, 2011). In addition, newer, constructivist, philosophical 
developments lead to questions with respect to the relatively mechanistic assumptions 
postulated by CBT. Altogether, these issues represent the breeding ground for discontent 
around the current mainstream. At the same time, it has been suggested that a potential 
avenue toward better therapy development may include a focus on the function of 
problematic cognitions and behaviors, and on a model of behavior that is more contextual, 
non-mechanistic, more consistent with evolutionary theory, and radically pragmatic (Hayes 
2004a). 
Under the broad umbrella term “third wave” there are forms of CBT that represent 
both an extension of and innovation within CBT. These therapies, some of them developed 
in the 1990s, are generally less focused on reducing psychological and emotional 
symptoms, although it is a consistent “side-benefit”. These therapies do not have first-order 
change as their only objective, they are contextualistic, use experiential and indirect change 
techniques besides direct strategies, and have a broad focus of change (Hayes, 2004ab). 
Aspects of context here are broad, including environment, therapeutic relationship, and 
person (Pérez-Alvarez, 2012). According to Dimidjian et al. (2016), from 2004 to 2015, 
the “third wave” label has been linked to the following treatment approaches: Acceptance 
and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), Dialectical Behavior 
Therapy (DBT; Linehan, 1993), Mindfulness-Based Cognitive Therapy (MBCT; Segal, 
Williams & Teasdale,2013), Functional Analytic Psychotherapy (FAP; Kohlenberg & Tsai, 
1991), and Extended Behavioral Activation (eBA; Martell, Addis & Jacobson,2001), 
whereas there is some discrepancy of view about others, such as Cognitive Behavioural 
Analysis System of Psychotherapy (CBASP; McCullough, 2000), Compassion-focused 
Therapy (CFT, Gilbert, 2009), Mindfulness-Based Stress Reduction (MBSR; Kabat-Zinn, 
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1982), Mindfulness-Based Relapse Prevention (MBRP; Bowen, Chawla & Marlatt,2011), 
Mindfulness-Based Eating Awareness Training (MB-EAT; Kristeller & Hallett, 1999), 
Metacognitive Therapy (MCT; Wells, 1995), and Integrative Behavioural Couple Therapy 
(IBCT; Jacobson & Christensen, 1996). Hayes, Villatte, Levin and Hildebrandt (2011), 
recognizing some resistance and division created by the term "third wave" (Hoffman, 
Sawyer, & Fang, 2010) proposed the alternative term “contextual cognitive behavioral 
therapies”, but the term third wave has become so popular in the scientific literature that 
we use it here. Currently, there are contradictory opinions regarding the existence of a third 
wave of CBT that is replacing classical CBT. For example, for authors such as Hofmann 
and Asmundson (2008, p. 13), “there is no data to suggest that it (ACT) represents an 
entirely new treatment approach”. Of course, others would argue that the distinction is, at 
least initially, a philosophical one and not an empirical one (Hayes et al. 2011). A critical 
analysis of this issue is beyond the scope of this paper. 
Third-wave therapies have obtained promising results for some conditions, but at 
the same time, clear superiority over other well-established treatments is infrequently 
demonstrated (Churchill et al., 2013; Dimidjian et al., 2016; Hoffman et al., 2010; Hunot et 
al., 2013; Öst, 2008; Öst, 2014). In a pioneering meta-analysis of the scientific evidence 
and methodological quality of third-wave CBT (including ACT, DBT, CBASP, FAP, and 
IBCT) for psychiatric disorders, Öst (2008) found that the total effect size for the third-
wave RCTs was .56. Öst (2008) concluded that the third-wave therapies provide a 
significant moderate effect size, but they are limited by a lack of methodological quality of 
RCTs conducted to test them. More recently, Dimidjian et al (2016) carried out a search 
for meta-analyses of the therapies most frequently identified as third wave. Meta-analytic 
findings indicated that ACT showed superiority to a variety of control conditions. 
Regarding DBT, there was no strong indication in this study that it provides incremental 
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benefit over first- or second-wave CBT. Concerning MBCT, results indicated a significant 
reduction of depression relapse across studies. Finally, eBA did not obtain compelling 
indication that it outperforms second-wave CBT. The authors concluded that the therapies 
classified as third wave offer significant clinical benefit over some control conditions, but 
that more well-designed RCTs are needed. Currently, according to the definitions of “well 
established” and “probably efficacious” treatments (APA Presidential Task Force on 
Evidence-Based Practice, 2006; https://www.div12.org/psychological-
treatments/treatments/), only three third-wave therapies have achieved the status of “well-
established” treatments. Specifically, ACT, CBASP, and DBT have strong support for 
chronic/persistent pain, depression, and borderline personality disorder, respectively. 
Third-wave therapies address a wide variety of conditions, some of them extremely 
difficult to manage and very costly for the healthcare system and the society as a whole. 
For instance, DBT, CBASP and ACT are usually delivered to patients diagnosed of 
Borderline Personality Disorder (BPD), chronic major depression and chronic pain, 
respectively. Patients with BPD, chronic major depression or chronic pain consistently 
show high patterns of healthcare service utilization and therefore carry high costs (Leadley, 
Armstrong, Lee, Allen, & Kleijnen, 2012; Meuldijk, McCarthy, Bourke, & Grenye, 2017; 
Pincus & Pettit, 2001). 
How third-wave therapies are supposed to work 
The second-wave of psychological therapies are based on a classical biomedical 
model in four meanings (Pérez-Alvarez, 2012): internal perspective (information 
processing), causal mechanism (dysfunction in psychological functioning), management 
based on resolving the underlying dysfunctions, and effectiveness criteria (improvement of 
symptoms). In contrast, third-wave therapies are much less based on pathology or 
symptom-focused models, explaining the psychological problems in interactive, functional 
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and contextual terms (Kahl, Winter, & Scweiger, 2012). So, it is assumed that 
psychological problems emerge from the individual in his/her interaction with specific 
internal-external circumstances. For the contextual model of psychological therapy, the 
focus is not on symptom reduction. Instead the focus is on reducing experiential avoidance, 
increasing contact with the present moment, increasing acceptance, openness, and 
engagement with values (Hayes, 2004ab). Whereas in second-wave CBT the objective of 
identifying unwanted thoughts is to change them, in third-wave CBT the aim is to change 
the subject’s relationship with unwanted thoughts and feelings so that experiential 
avoidance is decreased. They also include training in mindfulness techniques to improve 
awareness and a focus on the present moment. This is also intended to decrease restrictive 
or avoidance-coordinating effects of thoughts, and allow behaviour to be better regulated 
but the situation at hand. More conventional behavioural strategies also can be employed to 
help individuals to commit, rehearse, apply, and integrate behaviour change according to 
their goals and values. 
The importance of economic evaluations  
Economic evaluations describe the costs and effects of alternative treatments and are a 
useful tool for public health decision making. Policy-makers are faced with limited economic 
resources and routinely have to prioritize available treatments or choose among different 
alternatives (Haycox, 2009). In health economics, different analytic approaches are used for 
economic evaluation (cost-effectiveness, cost-utility, cost–benefit analysis, cost-minimization, 
and cost–consequences analysis) in order to compare alternative courses of action or 
treatments, in terms of costs and outcomes. The choice of analytic approach and outcomes 
used depends on the decision that analysts intend to influence (Drummond, Sculpher, 
Torrance, O’Brien, & Stoddart, 2005). In cost-effectiveness analysis, natural unidimensional 
index of outcomes are used (e.g. points in a scale measuring depression severity); in cost-
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utility analysis, the primary outcome is the cost per QALY (quality-adjusted life-years; which 
combine duration of life and the health-related quality of life); Cost–benefit analysis provides 
a monetary value to outcomes, and cost–consequences analysis includes a profile of outcomes 
for each alternative but does not combine the outcomes into a single unit of effect. Cost-
effectiveness and cost–utility analysis are the analytic approaches most commonly used by 
decision-makers, being the last the alternative of choice for comparing the value of 
interventions that have very different health benefits (Konnopka et al., 2012).  
Why it is important to perform this systematic review 
Although most forms of third-wave CBT appeared 10 or more years ago, the number 
of well-designed economic evaluations of these therapies in RCTs is not known and may be 
few. The great interest in these relatively new therapies among clinicians and researchers, as 
evidenced by recent meta-analyses of clinical outcomes in recent years (Churchill et al., 2013; 
Dimidjian et al., 2016; Hunot et al., 2013), suggests a need for demonstrating whether they 
must be prioritized by policy-makers or regulatory bodies when deciding which option is the 
most efficient for the treatment of a particular patient group. As Churchill et al. (2013) 
pointed out, assessment of economic impact of third-wave therapies is a priority. To address 
the potential efficiency of third-wave therapies as standalone or add-on treatments is a subject 
of crucial importance for the implementation of these therapies in actual practice (Demarzo, 
Cebolla, & García-Campayo, 2015). However, as far as we know, despite the great popularity 
of these therapies, no systematic review of economic evaluations has been performed. In this 
study, we first perform a systematic literature review of economic evaluations alongside 
RCTs of third-wave treatments to determine whether they generate significantly greater health 
benefits, relative to costs, for the health care system and for society as a whole compared to 
usual care or other well-established treatment options. Second, we critically appraised the 
methodological quality and potential risk of bias of the included studies using the 
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Drummond’s checklist for economic evaluations and the Cochrane risk of bias tool, 
respectively. 
Material and Methods 
The review protocol was registered at PROSPERO in April 1
st
 2016 (registration 
number: CRD42016037216), which is an electronic database of prospectively registered 
systematic reviews in health and social care. PROSPERO is funded by the UK National 
Institute for Health Research (http://www.crd.york.ac.uk/prospero/). We report this systematic 
review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
guidelines for systematic reviews (PRISMA; Moher et al., 2009). 
Search strategy 
We performed the literature search in the following electronic bibliographical 
databases: PubMed/Medline, PsychINFO, EMBASE and CINAHL. We searched manuscripts 
published in peer-reviewed journals at any time from the inception of the databases until May 
1st 2016. Terms related to `third-wave´ therapies and economic evaluations were employed, 
without using limitations a priori (e.g. ‘humans’ or ‘English’ language). There were no 
restrictions related to age. For the full specific syntax in each database see Supplementary file 
1. A secondary search strategy was performed by contacting experts in this field, by searching 
in Google Scholar, and by consulting tables of contents for journals that usually publish 
evaluations of third-wave CBT and reference lists of identified economic studies. 
Inclusion and Exclusion Criteria 
A consensus was reached among coauthors on which therapies should be included or 
excluded. As Hunot et al. (2013) pointed out, one key feature of these therapies certainly it 
their predominant focus on modifying the function of thoughts and feelings rather than on 
modifying the frequency or form of these thoughts and feelings, or their content. For the 
purposes of the current systematic review, the following therapies were included: ACT, DBT, 
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MBCT, FAP, eBA, CBASP, CFT, MBSR, MBRP, MB-EAT, MCT, and IBCT. An outline of 
these therapies is provided in Supplementary file 2. 
The obtained titles and abstracts were separately screened for eligibility by two 
coauthors (A.F-S and J.V.L). Full text of all potentially related manuscripts where the abstract 
did not provide enough details to confirm eligibility, were downloaded, examined, and 
discarded from the systematic review if they did not meet the inclusion criteria. References of 
systematic reviews and references of the included papers, were also examined in depth and 
cross-checked. After duplicates were removed, data extraction of included papers was made 
by two independent researchers (A.F-S and J.V.L) using a standardised data extraction form 
with any disagreements resolved through discussion. Disagreements not resolved by the two 
coauthors were arbitrated by a third coauthor (F.D). Only published randomized controlled 
trials (RCTs) incorporating economic evaluations of `third-wave´ CBT (ACT, eBA, CFT, 
DBT, MCT, CBASP, FAP, IBCT, MBCT, MB-EAT, MBRP, and MBSR), compared with a 
passive or active control group, were included. Non-randomized studies, such as quasi-
experimental designs or pre–post comparisons were excluded to maximize study quality and 
due to the high risk of selection bias associated with non-randomised study designs. RCTs had 
to have an adequate control condition: waiting-list, treatment-as-usual (TAU), sham 
intervention, a pharmacological treatment, or an alternative psychological treatment such as 
conventional CBT. Only full economic evaluations in which both the cost and consequences 
of two or more treatments are compared were included. Modelling studies were not included 
due to methodological differences with economic evaluations in RCTs (estimated and 
synthesized data instead of obtained raw data) that could threaten the internal validity of the 
present review. Literature reviews, books, dissertations, commentaries, conference abstracts, 
study protocols, case-reports, qualitative studies, non-peer-reviewed manuscripts and non-
English or non-Spanish papers were also excluded. We excluded unpublished dissertations, 
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master's theses, or conference presentations because restricting our analyses to RCTs 
published in peer-reviewed journals increased the likelihood that studies would be of at least 
minimal acceptable quality and relatively accessible. 
Study measures 
Quality assessment for the economic evaluations. Quality assessment was based on 
the Drummond 35-item checklist (Drummond & Jefferson, 1996). This checklist is 
recommended by the Cochrane Handbook for Systematic Reviews of Interventions for 
critical appraisal of the methodological quality of health economic evaluations and is the 
most widely employed tool (Frederix, Severens, & Hövels, 2015). It is crucial to use this 
type of quality assessment tools in the field of economic evaluation because they enable 
decision-makers to know the reliability and validity of data. It comprises 35 items divided 
into 3 sections: study design (7 items), data collection (14 items) and analysis and 
interpretation of results (14 items). Each item can be completely satisfied (Yes) or not 
(No), not clearly reported (Not clear) or Not applicable. Given that we excluded modelling 
studies, items 20 and 21 focused on ‘modelling’ were not appropriate. One author (J.V.L) 
completed the 35-item checklist for each study, which was subsequently reviewed by 
another author (A.F-S or F.D). None of the authors assessed papers to which he/she had 
participated as coauthor. All disagreements were resolved through discussion. We coded 
“Yes” as a 1 and No or Not clear as 0. We did not divide the %-scores into arbitrary 
categorisations of excellent, good and poor quality studies -  the tool was developed as an 
aid to reviewers and not as a measure of quality and 100% adherence does not indicate a 
perfect study. The items concern whether particular data has been recorded and it was 
possible for a poorly designed evaluation to report well. Following Donker et al. (2015), a 
global adherence to the checklist equal or greater than 75% was considered to be indicative 
of moderate to high-quality study (in cases where a ‘not applicable’ answer was logged, 
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the item was excluded from the denominator). Based on a systematic review of quality 
assessment tools for conducting and reporting health economic evaluations the Drummond 
checklist appears to possess sound inter-rater reliability and test-retest reliability (Walker 
et al., 2012) 
Risk-of-bias (RoB) assessment. Several tools have been designed to assess the 
validity/quality of RCTs. We assessed the stringency of the included RCTs using the 
Cochrane Collaboration’s risk of bias assessment tool (Higgins et al., 2011) because it 
assesses conduct (and not reporting), is based on theoretical and empirical evidence, and 
on broad consultation, and because it facilitates the transparent assessment of bias 
(Jørgensen et al., 2016). This carefully designed tool involves assessment of RoB arising 
from each of six domains: (a) selection bias, (b) performance bias, (c) detection bias, (d) 
attrition bias, (e) reporting bias, and (f) other bias (bias related to other issues: therapist 
qualifications, treatment fidelity and researcher allegiance/conflict of interest). The 
selection of these domains for inclusion in the assessment tool was based on the empirical 
evidence of their association with effect estimates (Higgins et al., 2011). The intention of 
the developers was to assess the validity of results based on the design and performance of 
the study, rather than reporting. The RoB tool was applied to each RCT independently by 
two reviewers (AFS and JVL) and any discrepancies were resolved through discussion 
with a third author. Each RCT was scored against the above criteria to provide a score of 
between 1 and 6. RCTs were classified as high risk (if at least one domain was assessed as 
high), unclear (if at least one domain was assessed as unclear and the other domains were 
low), or low risk of bias (if all individual domains were low). The Cochrane 
Collaboration’s risk of bias assessment tool has been employed in many Cochrane reviews, 
yielding a range of inter-rater agreement for the individual domains from poor (kappa κ = 
.13 for selective reporting) to substantial (κ = .74 for sequence generation) (Hartling et al., 
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2009). Our raters used the Cochrane Handbook guidelines for risk of bias assessments to 
standardize the decision-making process (Higgins & Altman, 2008). 
Outcome measures. Any economic evaluation needs to consider carefully which 
outcome measures are important when evaluating treatments. In this field, a good practice 
is to use generic (non-disease-specific) outcome measures so as to help decision-making on 
resource allocation across diseases or disorders (Drummond et al., 2005). In general, the 
most recommended and common outcome measure for cost-utility analysis (CUA) is the 
quality-adjusted life years (QALYs) (Vergel & Sculpher, 2008). QALYs represent an 
effort to take into account measures of both mortality and morbidity generated by 
healthcare interventions. A QALY places a weight on time in different health states. Thus, 
a year of perfect health is worth 1 and a year of less than perfect health is worth less than 1. 
QALYs provide a common metric to assess the extent of the benefits gained from different 
treatments in terms of HRQoL and survival for the patient. Outcome measures for the cost-
effectiveness analysis (CEA) are very heterogeneous and might include reduction of 
psychological symptoms, somatic symptoms, alcohol use, sleep disorders, self-harm 
behaviours, etc., as assessed with standardized instruments with sound psychometric 
properties. Other outcome measures can be the years lived with disability (YLD), health-
adjusted life expectancies (HALEs), and disability-adjusted life years (DALYs). 
Economic evaluation estimates 
CEA results are commonly expressed in cost-effectiveness ratios (CER) while CUA 
are usually summarized in cost-utility ratios (CUR), where the costs in the numerator are 
combined to a specific common measure of effectiveness or utility in the denominator 
(Van Hout, Al, Gordon, & Rutten, 1994). When two interventions are compared using 
these ratios, there are called incremental cost-effectiveness ratio (ICER) or incremental 
cost-utility ratio (ICUR). ICER provides an estimate of the cost for one additional unit of 
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improvement when administering the new treatment compared to the control using the 
formula: (Cost test intervention – Cost control intervention) / (Effect test intervention – 
Effect control intervention). ICUR indicates the cost of 1 QALY gained with the new 
treatment compared to the control treatment. 
In health economics, costs can be determined from different perspectives including 
the societal perspective, the funding source perspective, the patient/family perspective, or 
the clinician perspective (Gold, Siegel, Winstein & Russell, 1996). It is crucial to 
determine which perspective is taken in the evaluation to know what costs have to be 
included in the analysis. For instance, from the societal perspective all costs and outcomes 
that affect everyone in society, regardless of who pays, are included (total medical costs for 
resource use, productivity losses and out-of-pocket expenditures). Another important index 
is the willingness to pay (WTP), an indicator for the acceptability of the new treatment 
compared to the control treatment. Society’s WTP establishes the threshold to consider the 
new treatment as cost-effective. This WTP or investment ceiling is country-specific 
(Shiroiwa et al., 2010). To deal with uncertainty in the estimates, it is usual to show cost-
effectiveness acceptability curves (CEACs), which represent the probability that the 
intervention is cost-effective compared to the control condition, given a varying threshold 
for the WTP for a clinical outcome or a QALY.  
Data analyses 
Main results of economic evaluations are provided in local currency units, which 
are the most relevant to local decision-makers. Additionally, for the purpose of ICURs 
comparisons, local currency were inflated to the year 2014 and converted into international 
dollars (Int$) using purchasing power parity (PPP) exchange rates 
(http://wdi.worldbank.org/table/4.16). PPP indicators are calculated by comparing the cost 
of living, domestic goods and services in countries across the world. Given the 
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heterogeneity of the costing methods and the therapies, a meta-analysis was not conducted. 
We computed inter-rater agreement using kappa (κ) statistics for inclusion/exclusion of 
studies, global quality assessment, and overall RoB assessment. Agreement was graded as 
follows: poor (.00), slight (.01–.20), fair (.21–.40), moderate (.41–.60), substantial (.61–
.80), and almost perfect (.81–1.00). 
Results 
Selection and inclusion of studies 
The systematic literature search identified 1,342 articles (765 abstracts in total, after 
removal of duplicates). 730 articles were excluded in the process of title and abstract 
screening. 35 potentially eligible full-text papers were examined in detail for further 
consideration, and 24 of these were excluded. Finally, 11 RCTs met the inclusion criteria. 
There was an “almost perfect” inter-rater agreement between the two raters (kappa: κ = 
0.85). See Figure 1 for a flowchart of the process. 
Insert Figure 1 
Characteristics of included RCTs 
Table 1 shows a summary of study characteristics. The eleven RCTs included a 
total of 1,794 outpatients. The sample sizes of the study arms ranged from 19 to 221 
participants. The included RCTs were carried out in six different countries: the UK (n = 6), 
the Netherlands (n = 1), Australia (n= 1), Sweden (n= 1), Spain (n= 1) and the USA (n= 1). 
The studies analysed five types of third-wave therapies: MBCT (n= 5), ACT (n= 2), eBA 
(n = 2), DBT (n= 1), and MBSR (n= 1). The treatment lengths varied from six weeks to 12 
months. Time horizons for economic outcomes were three to 26 months. Studies used 
maintenance antidepressant medication (n= 2), TAU (n= 4), waiting-list (n= 2), active 
monitoring (n= 1), applied relaxation (n= 1), CBT (n= 1) or recommended 
pharmacological treatment (n= 1), as control comparison conditions. Target diseases and 
RUNNING HEAD: ECONOMIC EVALUATION OF THIRD-WAVE CBT 16 
 
 
 
disorders were history of major depression (n= 3), active major depression (n= 2), 
somatoform disorders (n= 1), multiple sclerosis (n= 1), unspecific chronic pain (n= 1), 
fibromyalgia (n= 1), personality disorders (n= 1) and history of breast cancer (n= 1). All 
studies performed full economic evaluations
1
 and four studies “discounted”2 costs. 
Insert Table 1 
Economics evaluations 
A summary of main cost-effectiveness/cost-utility outcomes of the included RCTs 
is provided in Table 1. It is important to point out that only 3 studies reported both CEA 
and CUA (Bogosian et al., 2015; Ekers et al., 2011; Kuyken et al., 2015), whereas 4 
studies computed only CEA (Kemani et al., 2015; Kuyken et al., 2008; Priebe et al., 2012; 
Shawyer, Enticott, Özmen, Inder & Meadows, 2016) and four studies only CUA 
(Lengacher et al., 2015; Luciano et al., in press; Richards et al., 2016; van Ravesteijn et al., 
2013). All CUA studies calculated QALYs as their primary outcome measure, the majority 
assessed with the European Quality of Life (EuroQol) instrument (EQ-5D-3L; EuroQol 
group, 1990). Only two studies used other measures: the Short-Form Six-Dimension (SF-
6D; Brazier, Usherwood, Harper, & Thomas, 1998) and the 12-Item Short Form Survey 
Instrument (SF-12v1; Ware, Kosinski, & Keller, 1996). As shown in Table 1, the CEA 
studies employed heterogeneous instruments for clinical outcomes. 
MBCT 
The five economic evaluations based on RCTs of MBCT for adults with different 
conditions are presented in Table 1. All studies focused on specific populations: non-
                                                          
1
In partial economic evaluations only the costs of at least two treatment alternatives are compared. This type of 
evaluation is also called cost analysis. A full economic evaluation does not only compare costs of at least two 
alternatives but also their effects measured in natural units (e.g. self-harm events avoided), artificial units 
(quality-adjusted life years or disability-adjusted life years) or monetary units. 
2
Discount= Converting future costs and effects to present values. It reflects the conventional view that 
individuals put a higher value on resources used today than at some point in the future (Detskie & Naglie, 1990)  
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depressed individuals with three or more previous major depressive episodes, somatoform 
disorders, and multiple sclerosis. The time horizon of the studies ranged from 3 months to 
26 months. Regarding combination therapy, combination of MBCT and antidepressant 
discontinuation was a cost-effective option in Kuyken et al. (2008), but these results were 
not replicated with a larger sample in Kuyken et al. (2015). In this well-designed full RCT 
with MBCT delivered during eight 2.25 h group sessions + four refresher sessions, all 
implemented in different settings (research clinical facilities, hospital sites, and the 
community), the ICER and the ICUR indicated that MBCT-TS had a low probability 
(below 60%) of being cost-effective in comparison to maintenance antidepressant 
medication. MBCT was even dominated in the cost-utility analysis. In contrast, compared 
to relapse monitoring (self-monitoring using the Patient Health Questionnaire-2 and -9), 
the combination of MBCT (eight 2-hour group sessions plus 3-monthly optional ‘booster 
sessions’) and depressive relapse monitoring showed a high probability of cost-
effectiveness from a mental health perspective in a recent Australian study (Shawyer et al., 
2016). A Dutch study by van Ravesteijn et al. (2013) reported on results of an RCT to 
assess the cost-effectiveness of MBCT (eight 2.5-hour sessions plus a silent retreat 
delivered by MBCT experienced instructors) for a group of patients with heterogeneous 
medically unexplained symptoms. The participants were frequent attenders (top 10% most 
frequently attending patients of the participating family physicians). MBCT had a low 
probability (below 60%) of being cost-effective taking different investment thresholds into 
account. More recently, a pilot study (Bogosian et al., 2015) based on a skype-delivered 
MBCT approach adapted for patients suffering multiple sclerosis (eight one-hr group 
sessions by videoconference over an eight-week period) was “dominant”3 in comparison to 
                                                          
3
Dominant= when intervention A results in improved clinical outcomes and lower resource utilization than 
intervention B, it is considered that A is dominant and should be adopted (Detskie & Naglie, 1990). 
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waiting-list using both clinical units (GHQ scores) and QALYs as treatment outcomes. 
These findings showed a high probability (> 90%) of cost-effectiveness at 3-month follow-
up.  
ACT 
Kemani et al. (2015) randomized Swedish adults with unspecific longstanding pain 
to ACT or applied relaxation (AR), both treatments delivered during 12 weeks (12 weekly 
group sessions of 90 min.), with pain disability the primary outcome measure. These 
authors assessed cost-effectiveness by computing the quotient of the difference in mean 
changes in costs and pain disability in ACT and AR. ICERs revealed that ACT was more 
cost-effective than AR after treatment and three-month follow-up, but these results were 
not maintained at six-month follow-up. Of interest are also the results of ACT as stand-
alone therapy published by Luciano et al. (in press), who found that a group-based form of 
this therapy (eight 2.5h sessions) was cost-effective for Spanish FM patients recruited in 
primary care centres in comparison to recommended pharmacological treatment (RPT; 
pregabalin + duloxetine in case of comorbid major depression) regardless of whether the 
type of analysis performed [intention-to-treat (ITT), completers or per protocol] or the 
economic perspective (healthcare system or societal). To sum up, in comparison to active 
psychological treatments (AR) and recommended medications (RPT), there are promising 
cost-effectiveness findings for ACT in chronic pain patients.  
eBA 
A pilot RCT (Ekers et al., 2011) showed results for the comparison of eBA 
(delivered by qualified mental health nurses with no previous formal psychotherapeutic 
training or experience) with TAU in a small sample of UK adults with persistent severe 
depression associated with substantial functional impairment. Compared with TAU, 12 
one-hour face-to-face sessions of eBA were more cost-effective in two possible scenarios 
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(scenarios A and B were proposed on the basis of two estimates of workload taking 
Improving Access to Psychological Therapy, or IAPT, service specifications into account). 
The authors concluded that eBA is both clinically effective and cost-effective over a short 
period of 3 months (> 95% probability at a UK threshold of UK£20,000). In a recent large-
scale non-inferiority RCT (the COBRA trial), Richards et al. (2016) showed that eBA 
(delivered by junior mental health workers) was non-inferior to CBT (delivered by highly 
trained professionals) in reduction of depression symptoms, depression status, depression-
free days and anxiety diagnoses. From the UK NHS/personal social services perspective, 
costs were lower and QALY outcomes better in the eBA study arm, therefore eBA was 
cost-effective in comparison to CBT. eBA remained cost-effective in all sensitivity 
analyses (e.g. including productivity losses). 
DBT 
Priebe et al. (2012) examined whether DBT delivered during 12 months was cost-
effective in UK patients referred to the DBT service in the London Borough of Newham, 
who had personality disorders characterized by self-harm behaviours (the majority had 
borderline personality disorder). Self-harm was “any act which the individual performed 
with the intention of self-harm, and caused tissue damage”. Compared to TAU delivered 
free of charge under the NHS, at 12 months there was a non-significant trend towards 
higher total costs (including lost employment costs) and significant better outcomes for 
DBT. Specifically, the authors found an ICER of $55 per one percent point reduction of 
self-harm. As there are no accepted threshold values for cost per percent point reduction of 
self-harm incidence we abstain from an interpretation. 
MBSR 
Among US breast cancer survivors with a previous diagnosis of stage 0, I, II, or III 
and who had completed treatment within two years prior to study enrolment, Lengacher et 
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al. (2015) compared MBSR (six-weekly two-hour format, excluding the one-day, eight-
hour retreat) with TAU, which consisted of standard post treatment clinic visits, with 
patients specifically asked not to use or practice mindfulness/meditation. At three-month 
follow-up, MBSR was more cost-effective than TAU from the provider and patients’ 
perspective. However, in the absence of any data on WTP, it is difficult to draw 
conclusions regarding the cost-effectiveness of MBSR. 
Quality assessment of economic evaluations 
Information about the quality of the identified RCTs is shown in Table 2. Overall, 
the methodological quality of the economic evaluations was acceptable to good, but there 
was some heterogeneity among studies. On average, the global adherence to the checklist 
was 78.1%. The minimum percentage of adherence fulfilled was 58.3% (Ekers et al., 2011) 
and the maximum percentage of adherence met was 100% (Kuyken et al., 2015). Seven of 
the included studies (64%) adhered to ≥ 75% of the guideline and achieved a rating of 
good quality. Agreement regarding global adherence/non adherence to the checklist was 
“almost perfect” (κ= .90). 
Most studies, with the exception of Ekers et al. (2011), had a well-defined research 
question, but the economic importance of the research question was not generally provided 
(Bogosian et al., 2015, Ekers et al., 2011; Kuyken et al., 2008). All studies mentioned the 
economic perspective but the viewpoint of the analysis was not clearly justified in all cases 
(Bogosian et al., 2015; Kemani et al., 2015; Kuyken et al., 2008; Shawyer et al., 2016; van 
Ravesteijn et al., 2013). All authors reported on the effectiveness of the third-wave therapy 
being tested, identified the most important costs and consequences for each condition, 
measured costs and consequences accurately, and valued the costs using reliable sources. 
Not all studies included a comprehensive description of the competing alternatives (Ekers 
et al., 2011; Shawyer et al., 2016). Only two studies provided sufficient information on 
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quantities of health service utilization (Kuyken et al., 2015; Priebe et al., 2012). Similarly, 
only thee studies justified the choice of variables for the “sensitivity analysis”4 as well as 
the ranges over which the variables were varied (Ekers et al., 2011; Lengacher et al., 2015; 
Richards et al., 2016). These were the least frequently fulfilled criteria. Finally, two studies 
were rated unfavourable because of the absence of major outcomes presented in aggregated 
and disaggregated form (Bogosian et al., 2015; Lengacher et al., 2015). 
Insert Table 2 
Risk-of-bias assessment 
Figure 2 shows risk of bias for each included RCT. We reached a “substantial” 
level of agreement between raters (κ= 0.75). All of the studies (11/11) reported an adequate 
random sequence generation. However, the majority of the trials (6/11) provided 
insufficient information on the method of allocation concealment from patients. Authors 
made a great effort for blinding research staff and outcome assessors, but given the nature 
of the interventions, blinding of participants from knowledge of which intervention they 
were receiving was not possible at all. Incomplete outcome data were adequately managed 
by six included RCTs. All of the included trials were rated as free from selective outcome 
reporting bias (11/11), but a vast majority presented other sources of bias (unclear or high 
risk of bias in this item). Taking into account that is almost impossible to blind participants 
in a RCT testing a psychological treatment, only two studies (Kuyken et al., 2015; 
Richards et al., 2016) demonstrated a low global risk of bias. The overall RoB of the other 
constituent studies were unclear or high. 
Insert Figure 2 
Discussion 
                                                          
4
Sensitivity analysis= method for testing the stability of a cost-effectiveness/cost-utility ratio over a range of 
estimates and assumptions. A range of ratios is calculated by substituting a range of estimates for each of the 
variables of the cost-effectiveness/cost-utility ratio (Detskie & Naglie, 1990). 
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The first main finding is that there is a need for further economic evaluations of 
third-wave therapies given that only eleven RCTs focusing on five of these therapies 
(MBCT, MBSR, ACT, DBT, and eBA) were found. As Edwards, Bryning and Crane 
(2015, p. 491) pointed out, “An intervention cannot be cost-effective if it is not first 
clinically effective”. The clinical effectiveness of three of the five third-wave therapies 
(ACT, CBASP, and DBT) is currently well-established for some conditions (APA 
Presidential Task Force on Evidence-Based Practice, 2006). In the health economics arena, 
the number of economic evaluations of MBCT far outnumber those focused on the other 
third-wave therapies. 
Comparative cost-effectiveness determines if implementation of a treatment option 
is likely to be efficient or not. Disease-specific cost-effectiveness tables, along with 
assessments of the methodological quality of the included studies, represent the most 
important tool for policy makers in order to decide the most recommendable treatment. An 
inspection of available evidence indicates that compared to applied relaxation or 
recommended medications, ACT is a dominant treatment option for chronic pain patients 
(Kemani et al., 2015, Luciano et al., in press). In the case of Luciano et al’s study (in 
press), it might have been also very interesting to assess ACT as an aggregated component 
of usual care rather than as an alternative to recommended pharmacological treatment. The 
same can be said in the case of some MBCT trials (Kuyken et al., 2008; Kuyken et al., 
2015). A more appropriate real-world question could have been whether receiving MBCT 
in addition to maintenance antidepressant drugs is cost-effective compared to maintenance 
antidepressant drugs as standalone treatment. Focusing on MBCT, findings are 
inconclusive because of the presence of very positive results in some trials (Bogosian et al., 
2015, Shawyer et al., 2016) and modest results in others (Kuyken et al., 2015; van 
Ravesteijn et al., 2013). In the specific case of relapse prevention in major depression, 
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MBCT was dominated by maintenance antidepressant medication in the cost-utility 
analysis performed by Kuyken et al. (2015). The other mindfulness based treatment 
(MBSR) obtained support for the care of breast cancer survivors taking a reasonable 
investment threshold into account (Lengacher et al., 2015). DBT was superior to usual care 
in the management of self-harm behaviours from a societal perspective (Priebe et al., 
2012). eBA delivered without the need of experienced and highly trained professionals was 
cost-effective compared to usual care for adults with depression (Ekers et al., 2011) and 
CBT (Richards et al., 2016). 
An important finding is the total absence of economic evaluations of MCT, 
CBASP, FAP, IBCT, CFT, MB-EAT, and MBRP. So, it seems necessary to begin to 
include and report on the costs and cost effectiveness of these third-wave therapies. In 
comparison to second-wave CBT, economic analyses of third-wave therapies are 
considerably underdeveloped. Selecting depression as target condition, Brettschneider et 
al. (2015) identified 22 studies performing cost-utility analyses of CBT. Their results 
showed that individualized CBT can be a cost-effective treatment from the perspective of a 
third-party payer at short-term for the acute treatment and prevention of major depression 
in an adult population and also obtained some evidence that the use of a societal 
perspective enhanced cost-effectiveness. Focusing on the effectiveness and cost-
effectiveness of CBT interventions delivered via internet, Hedman, Ljotsson, and 
Lindefors (2012) found that of the 108 RCTs included in their review, eight provided data 
on cost–effectiveness of the treatments in adult patients. Therefore, even narrowing the 
focus of interest (internet CBT), the number of economic evaluations alongside RCTs of 
second wave CBT is relatively high. We suspect that grant funding might be a plausible 
explanation for the fewer number of economic evaluations of third-wave therapies. We 
agree with Gaudiano (2009, p. 1067) when he stated that “…ACT and CBT interventions 
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are at very different stages of clinical trial testing, and thus ACT studies have historically 
had less funding to support this early research. In contrast, CBT clinical trials are in the 
most advanced stage of any psychotherapy outcome research to date”. This reasoning in 
favour of ACT can be extended to the other third-wave therapies. 
For the present review, we decided to exclude non-randomized studies owing to 
their susceptibility to bias. Unpublished studies were also excluded as numbers enrolled 
may vary between unpublished data and final publications. According to an anonymous 
reviewer this is a potential limitation. Due to the expected low number of economic 
evaluations alongside RCTs, the inclusion of non-randomized or unpublished studies could 
have provided additional interesting data in this nascent field. 
It appears interest in economic evaluations of third-wave CBT is growing. There 
are numerous upcoming economic evaluations that will reinforce the available evidence 
about MBCT, MBSR, ACT, DBT, eBA, and CBASP (for the first time). Ten references 
reporting on protocols for ongoing RCTs that seem to meet the inclusion criteria for a 
future third-wave CBT systematic review (see supplementary file 3). A future update of the 
present review we will be able to include findings from the ten ongoing studies that 
perform economic evaluations alongside a RCT: two are focused on MBCT, three on ACT, 
one on eBA, two on MBSR, one on DBT and one on CBASP. Of the ten studies that are 
currently assessing the cost-effectiveness of a third-wave therapy, nine have decided to 
adopt a societal perspective, as the target disorders are very heterogeneous. We can 
observe in this table that the well-established EQ-5D-3L, that is currently considered the 
leading generic measure of HRQoL worldwide is being replaced in some cases by the five-
level version (EQ-5D-5L) with the expectative of increasing sensitivity to change 
(Agborsangaya, Lahtinen, Cooke, & Johnson,2014).  
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The quality and risk of bias assessment revealed important shortcomings that 
temper the promising findings reported until now. The RCTs included in this systematic 
review present important limitations in terms of small sample sizes and absence of long-
term follow up. As pointed out by Shean (2014), sample sizes in psychotherapy trials are 
“frequently justified by power estimates based on questionable effect sizes reported in 
previous non-double-blind psychotherapy efficacy studies. These estimates are likely to be 
inflated by the effects of “therapist allegiance.” Third-wave therapies are no exception in 
this. We found small sample sizes (n< 50 by study arm) in 45% of the included RCTs. 
Regarding follow-ups, 64% of the trials were commonly limited to 12 months or less and 
the benefits of third-wave therapies may extend or diminish beyond these follow-up 
periods. In contrast, the cost-effectiveness of CBT has been compared to other equally 
active treatment options, including large samples, and long-term follow-ups. For instance, 
Egger et al. (2016) have demonstrated the cost-effectiveness of CBT at 30 months 
compared to psychodynamic therapy in the management in a large sample (n > 200 per 
study arm) of patients with social anxiety disorder. Another limitation is that most third-
wave treatment providers are not integrated into the existing health care systems. As is 
evident from this systematic review, the majority of studies do not address the 
generalizability and actual implementation of these therapies, a subject that is currently 
under debate (Demarzo et al., 2015). Some third-wave CBTs are challenging to implement 
in routine care. For example, the half-day retreat required by MBSR or the shortage of 
trained CBASP teachers represent serious obstacles for implementation. It would be very 
interesting if future studies address the staffing costs, training costs, venue overheads, and 
materials needed to implement third-wave treatments. Of great interest is also to know 
what is the cost of delivering third-wave CBT vs. first- or second-wave CBT, which may 
involve comparing the training of the teacher/instructor, running costs, including 
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supervision of clinicians and continuous professional development training; space needed 
to make the intervention; materials such as books or CDs for home practice; administrative 
support, and so forth. These comparisons are relevant to those wanting to make a case for 
the funding of third-wave CBT in the future and potential integration into routine care 
(Edwards et al., 2015). 
The economic analysis of third-wave therapies can be performed under the 
perspective of integrated care, assuming that they constitute complex interventions that 
need to be evaluated in “realist RCTs” (Fletcher et al., 2016). The main of our systematic 
review is not to provide lessons for how to design definitive, fully powered economic 
evaluations of third-wave therapies alongside RCTs for the future. Edwards et al (2015) 
have focused their efforts on this issue. The ten methodological considerations for the 
economic evaluation of mindfulness-based interventions described by these authors can be 
aptly extended to all third-wave cognitive behavioural therapies. For instance, these 
authors recommend “A cost utility or cost-effectiveness analysis embedded in a wider cost-
consequence analysis” (p. 494) in order to acknowledge the wider range of outcomes from 
a mindfulness-based intervention. As these authors pointed out, researchers should use the 
same  conventional outcomes as those used in most studies for the sake of comparability 
(e.g. QALY estimates), but is also crucial to include measures that capture the particular 
shift in functional performance outcomes, which are the core focus of acceptance and 
mindfulness-based training. We are aware that the inclusion of this type of outcomes in 
cost-effectiveness analysis is far from being easy because, for example, there are certainly 
no accepted threshold values for cost per point increase in aspects of psychological 
flexibility. Finally, last but not least, one common flaw in the economic evaluation of 
psychological therapies in general is that sample size per study arm is determined by 
clinical outcomes and not by economic outcomes. Unfortunately, a full economic analysis 
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needs a larger sample size than that needed for clinical analysis. The inclusion of health 
economists within multidisciplinary teams prior to beginning of the trials could help 
researchers to produce better quality economic studies.  
Conclusions 
To sum up, this is currently the only systematic review of the literature on the 
economic evaluation for third-wave CBT for the management of different physical and mental 
health conditions. This review also incorporated a quality and risk of bias assessment. There 
is economic data supporting some of the interventions usually labelled as “third-wave” CBT. 
However, our review suggests that further research with higher methodological quality is 
needed on the relative efficiency of different forms of “third-wave” CBT compared to other 
active treatments. 
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Table 1 
Full Economic Evaluations of 'Third-Wave' Cognitive and Behavioural Therapies 
Author 
(year); 
country 
'Third wave' 
psychotherapy 
Target condition 
Treatment arms 
(n); Delivery 
period 
Cost categories included 
(cost-perspective) 
Clinical 
effect or 
utility 
outcome 
Results of the economic 
evaluation 
Time 
horizon 
Kuyken et al. 
(2008); UK 
MBCT 
Non-depressed 
adults with three or 
more previous 
major depressive 
episodes 
(a) MBCT + 
antidepressant 
discontinuation 
(n= 61) 
(b) maintenance 
antidepressant 
medication (m-
ADM; n= 62) 
Delivery period: 8 
weeks 
Societal perspective. It included 
all hospital (inpatient, outpatient, 
emergency department) and 
community health and social 
services (e.g., primary care, 
social work, complementary 
therapies), plus productivity 
losses resulting from time off 
work due to illness. Discount 
rate: 0%  
SCID-I 
(proportion 
of patients 
who relapse) 
Cost-effectiveness analysis (ITT) 
ICER= $962 per 
relapse/recurrence prevented and 
$50 per depression-free day. 
From the healthcare perspective, 
the ratios were $439 and $23, 
respectively. 
WTP 
MBCT showed a 42% 
probability of being cost-
effective compared to m-ADM if 
the society would pay €0 for 
preventing and additional 
relapse/recurrence. MBCT has a 
high probability (> 80%) of 
being more cost-effective than 
has m-ADM for WTP ≥ $10,000 
15 
months 
van 
Ravesteijn et 
al. (2013); 
Netherlands 
MBCT 
Undifferentiated 
somatoform 
disorder 
(a) MBCT (n= 64) 
(b) Enhanced 
Usual Care (EUC; 
n= 61) 
Delivery period: 8 
Societal perspective. It covered 
employment participation, health 
care use per day, medication use, 
number of attended MBCT 
sessions. Discount rate: 0%. 
SF-6D 
Cost-utility analysis (completers) 
ICUR= €56,637 for a QALY 
gain, that is, MBCT was more 
costly and more effective than 
EUC (inflated and converted 
12 
months 
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weeks  
 
ICUR= Int$81,700) 
WTP 
MBCT had a 28% probability of 
being cost-effective compared to 
EUC if the society would pay €0 
for one gained QALY. And at a 
threshold of €40.000 and 
€80,000 this is 48% and 57%, 
respectively. 
Bogosian et 
al. (2015); 
UK 
MBCT 
Primary and 
secondary 
progressive 
multiple sclerosis 
(a) Skype distant-
delivered MBCT 
(n= 19) 
(b) Waiting-list 
control group (n= 
21) 
Delivery period: 8 
weeks 
Societal perspective. Direct 
intervention costs (resources and 
time spent by professionals 
providing the mindfulness 
sessions), health and social care 
costs (admission days, 
consultations, etc.) and informal 
care costs. Discount rate: 0% 
 
 
GHQ-12 
EQ-5D-3L 
Cost-effectiveness analysis (ITT) 
ICER not reported. Authors 
indicate lower costs and larger 
clinical effects (GHQ scores) in 
MBCT compared to waiting-list 
control at 3 months. 
Cost-utility analysis (ITT) 
ICUR not reported. Equal health 
gains in terms of QALY gained 
were generated for less costs by 
MBCT compared to waiting-list 
control at 3 months. 
WTP 
MBCT ≥ 90% probability of 
being cost-effective vs. waiting-
list control if society were 
willing to pay £20,000 for one 
additional QALY. 
3 
months 
Kuyken et al. 
(2015); UK 
MBCT 
Non-depressed 
adults with three or 
more previous 
(a) MBCT + 
antidepressant 
discontinuation 
Primary analysis from the health 
and social care perspective. 
Secondary analyses included 
SCID-I 
(proportion 
of patients 
Cost-effectiveness analysis 
(completers) 
ICER= £4,955 from the 
24 
months 
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major depressive 
episodes 
(MBCT-TS; n= 
212) 
(b) maintenance 
antidepressant 
medication (m-
ADM; n= 212) 
Delivery period: 8 
weeks 
productivity losses and out-of-
pocket expenditure. Discount 
rate: 3.5% 
who relapse) 
EQ-5D-3L 
NHS/Personal Social Services 
perspective and £10,604 from 
the societal perspective 
(including productivity losses 
and patient costs). These values 
would need to be invested in 
order to generate a unit reduction 
in the percentage of participants 
who relapse. 
WTP 
The probability of MBCT-TS 
being more cost-effective than 
m-ADM did not rise above 43%. 
Cost-utility analysis (completers) 
ICUR not reported. MBCT-TS is 
dominated by m-ADM, that is, 
MBCT-TS costs were higher and 
outcomes worse, on average, 
than m-ADM. 
WTP 
The probability that MBCT-TS 
was more cost-effective than m-
ADM did not rise above 52%. 
Shawyer et 
al. (2016); 
Australia 
MBCT 
Non-depressed 
adults with a 
history of three or 
more major 
depressive episodes 
(a) MBCT + 
DRAM 
(depressive relapse 
active monitoring; 
n= 101) 
(b) Control 
(DRAM; n= 102) 
Analysis from the mental 
healthcare, health care, and 
societal perspectives. Costs 
included were delivery of MBCT, 
prescribed medications, hospital, 
community health and social 
service contacts, productivity 
CIDI 2.1 
(days in 
MDEs) 
ICD-10 
Cost-effectiveness (ITT; societal 
perspective) 
ICER= -AUD156. This value 
reflects savings (less costs) 
achieved by MBCT compared to 
the control to avert a day of 
major depression in one person. 
26 
months 
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Delivery period: 8 
weeks 
loses, and out-of-pocket 
expenses. Discount rate: 3% 
 
 
In addition, MBCT produced -
AUD164,758 as saving per 
person each year by averting a 
DALY.  
WTP 
Not reported from the whole of 
society perspective. From the 
mental health care perspective, 
MBCT= 81% probability of 
being cost-effective vs. control if 
decision makers were willing to 
pay AUD0 for an extra point 
increase in DALY. 
Kemani et al. 
(2015); 
Sweden 
ACT 
Unspecific, 
longstanding pain. 
(a) ACT (n= 30) 
(b) Applied 
Relaxation (AR; 
n= 30) 
Delivery period: 
12 weeks 
Analysis from the societal 
perspective. Data obtained in 3 
different domains: (1) direct 
medical costs, comprising costs 
related to healthcare utilization, 
medication use + intervention 
costs (2) direct non-medical 
costs, and (3) indirect nonmedical 
costs (employment status, sick 
leave, and reduced capacity at 
work and domestically) Discount 
rate: 0% 
PDI 
Cost-effectiveness (ITT; societal 
perspective) 
ICER at 6.months not reported. 
No differences in costs or 
effectiveness between the two 
treatments. 
ICER (3 months) = -$648. Each 
incremental improvement on the 
PDI for ACT participants 
relative to AR yielded a societal 
earning of $648 at 3 months. 
WTP 
Not reported 
6 
months 
Luciano et 
al. (in press); 
Spain 
ACT Fibromyalgia 
(a) ACT (n= 51) 
(b) Recommended 
pharmacological 
treatment (RPT; n= 
Analyses performed from the 
healthcare (self-reported data 
collection about medication 
consumption, medical tests, use 
EQ-5D-3L 
Cost-utility analysis (ITT; 
societal perspective) 
ICURs not reported. ACT was 
found to be dominant when 
6 
months 
RUNNING HEAD: ECONOMIC EVALUATION OF THIRD-WAVE CBT 43 
 
 
 
52) 
(c) Waiting-list 
(WL; n= 53) 
Delivery period: 8 
weeks 
of health-related services, and 
cost of the staff running the ACT 
intervention) and from a 
restricted societal perspective 
(productivity losses). Discount 
rate: 0% 
compared against RPT and WL. 
The average incremental cost for 
the comparison ACT vs. RPT 
was €-389.5. The incremental 
effect for QALYs was found to 
be around 0.01. 
WTP 
Not reported 
Ekers et al. 
(2011); UK 
eBA Major depression 
(a) eBA (n= 24) 
(b) TAU (n= 23) 
Delivery period: 
12 weeks 
Health care perspective. It 
included therapists’ costs, 
training costs, supervision costs, 
and total services use. Discount 
rate: 0% 
BDI-II 
EQ-5D-3L 
Cost-effectiveness analysis (ITT; 
health care perspective) 
ICER (Scenario A)= £9.45 per 
BDI-II point reduction 
ICER (Scenario B)= £11.04 per 
BDI-II point reduction 
Cost-utility analysis (ITT; health 
care perspective) 
ICUR (Scenario A)= £5006 per 
QALY (inflated and converted 
ICUR= Int$7644,7) 
ICUR (Scenario B)= £5756 per 
QALY (inflated and converted 
ICUR= Int$8790,2) 
WTP 
>95% probability that eBA is 
more cost-effective than TAU at 
a threshold value of £20 000 in 
both scenarios. 
3 
months 
Richards et al. 
(2016); UK 
eBA Major depression 
(a) eBA delivered 
by junior mental health 
workers (n= 221) 
Primary analysis from the UK 
National Health Service 
perspective. Sensitivity analysis 
EQ-5D-3L 
Cost-utility analysis (completers; 
UK NHS perspective) 
ICUR= –£6865 for a QALY 
18 
months 
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(b) CBT delivered by 
professional therapists 
(n= 219) 
Delivery period: 
16 weeks 
from the societal perspective 
(including productivity loses). 
Data collection on patients’ use 
of eBA and CBT from clinical 
records. Measurement of all other 
health and social care services 
used (community health and 
social care contacts, medication 
prescription and use), and 
productivity losses (absenteeism 
and presenteeism questions). 
Discount rate: 3.5% 
gain, that is, eBA costs were 
lower and QALY outcomes 
better compared to CBT 
(converted ICUR= -Int$9807) 
WTP 
eBA had a 75-80% probability of 
being cost-effective compared to 
CBT if the UK NHS would pay 
£20,000–30,000 per QALY. 
Cost-utility analysis (ITT; UK 
NHS perspective) 
Multiple imputation increased 
the ICUR= –£16,951 (converted 
ICUR= -Int$24,216) 
Priebe et al. 
(2012); UK 
DBT 
Personality 
disorders with self-
harm 
(a) DBT (n= 40) 
(b) TAU (n= 40) 
Delivery period: 
12 months 
Societal perspective. Service use 
included the number of days 
spent in hospital, outpatient 
visits, contacts with general 
practitioners and other 
community-based health 
providers, prescribed medication, 
and lost work time for those in 
employment. Discount rate: 0% 
SCI 
Cost-effectiveness analysis (ITT; 
societal perspective) 
ICER= £36GBP per one 
percentage point reduction in the 
incidence of self-harm rate as a 
result of using DBT (per 2-
month period). 
WTP 
Not reported 
12 
months 
Lengacher et 
al. (2015); 
USA 
MBSR 
Breast cancer 
survivors 
(a) MBSR (n= 49) 
(b) TAU (n= 47) 
Delivery period: 6 
weeks 
Provider and patient perspective. 
Accounting for both direct 
medical costs of the intervention 
and patient opportunity costs 
(time spent participating in the 
MBSR, time spent traveling to 
and from the intervention site, 
SF-12v1 
Cost-utility analysis (ITT) 
ICUR= $22,200 is the cost to 
provider per incremental gain in 
QALYs. $19,733 is the out-of-
pocket cost per incremental gain. 
The incremental gain during the 
12-week period was 0.03 
3 
months 
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participant transportation, 
childcare, meals and lodging for 
patients who travelled long 
distances) Discount rate: 0% 
QALYs. 
WTP 
Not reported 
 
Note: BDI-II= Beck Depression Inventory (); CIDI 2.1= Composite International Diagnostic Instrument 2.1 Auto Lifetime version; EQ-5D-3L= European Quality of Life (EuroQol) 
instrument in 5 dimensions (three level version); GHQ-12= General Health Questionnaire; SF-6D= Short Form Health Survey in 6 dimensions. Preference-based single index measure of 
general health based on the SF-36 and SF-12. The SF-6D enables the calculation of QALYs. PDI= Pain Disability Index; SCID-I= Structured Clinical Interview for DSM Axis I Disorders. 
SCI= Self-harm structured interview; SF-12v1= first version of the 12-item Short-Form Health Survey. 
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Table 2 
Quality of Studies Computing Cost-effectiveness/Cost-utility Analyses of 'Third-Wave' Cognitive and Behavioural Therapies. 
Quality checklist (Drummond & Jefferson, 1996) 
    
Kuyken et al. 
(2008) 
van Ravesteijn 
et al. (2013) 
Bogosian et 
al. (2015) 
Kuyken et al. 
(2015) 
Shawyer et 
al. (2016) 
Kemani et al. 
(2015) 
Study design       
1. The research question is stated. Yes Yes Yes Yes Yes Yes 
2. The economic importance of the research question is stated. Yes Yes No Yes Yes Yes 
3. The viewpoint(s) of the analysis are clearly stated and justified. No N.C No Yes Yes N.C. 
Selection of alternatives       
4. The rationale for choosing alternative programmes or interventions 
compared is stated. 
Yes No No Yes Yes Yes 
5. The alternatives being compared are clearly described.  Yes Yes Yes Yes Yes Yes 
Form of evaluation       
6. The form of economic evaluation used is stated. Yes Yes Yes Yes Yes Yes 
7. The choice of form of economic evaluation is justified in relation to the 
questions addressed. 
Yes Yes No Yes Yes Yes 
Effectiveness data       
8. The source(s) of effectiveness estimates used are stated. Yes Yes Yes Yes Yes Yes 
9. Details of the design and results of effectiveness study are given (if based on 
a single study). 
Yes Yes Yes Yes Yes Yes 
10. Details of the methods of synthesis or meta-analysis of estimates are given 
(if based on a synthesis of a number of effectiveness studies). 
N.A. N.A. N.A. N.A. N.A. N.A. 
Benefit measurement and valuation       
11. The primary outcome measure(s) for the economic evaluation are clearly 
stated. 
Yes Yes Yes Yes Yes Yes 
12. Methods to value benefits are stated. Yes Yes Yes Yes Yes Yes 
13. Details of the subjects from whom valuations were obtained were given. Yes Yes Yes Yes Yes Yes 
14. Productivity changes (if included) are reported separately. Yes Yes N.A. Yes No Yes 
15. The relevance of productivity changes to the study question is discussed. No No N.A. Yes No No 
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Costing       
16. Quantities of resource use are reported separately from their unit costs. No No No Yes No No 
17. Methods for the estimation of quantities and unit costs are described. Yes Yes Yes Yes Yes Yes 
18. Currency and price date are recorded. Yes Yes Yes Yes Yes Yes 
19. Details of currency of price adjustments for inflation or currency conversion 
are given. 
Yes No No Yes No No 
Modelling       
20. Details of any model used are given. N.A. N.A. N.A. N.A. N.A. N.A 
21. The choice of model used and the key parameters on which it is based are 
justified. 
N.A. N.A. N.A. N.A. N.A. N.A 
Adjustments timing of costs & benefits       
22. Time horizon of costs and benefits is stated. Yes Yes Yes Yes Yes Yes 
23. The discount rate(s) is stated. No N.A. N.A Yes Yes N.A. 
24. The choice of discount rate(s) is justified. No N.A. N.A Yes Yes N.A. 
25. An explanation is given if costs and benefits are not discounted. No N.A. N.A N.A N.A N.A. 
Allowance for uncertainty       
26. Details of statistical tests and confidence intervals are given for stochastic 
data. 
Yes Yes Yes Yes No Yes 
27. The approach to sensitivity analysis is given. No Yes N.A. N.A. Yes N.A. 
28. The choice of variables for sensitivity analysis is justified. No No N.A. N.A. No N.A. 
29. The ranges over which the variables are varied are justified. No No N.A. N.A. No N.A. 
30. Relevant alternatives are compared. Yes Yes Yes Yes N.C. Yes 
Presentation of results       
31. Incremental analysis is reported. Yes Yes Yes Yes Yes Yes 
32. Major outcomes are presented in a disaggregated as well as aggregated 
form. 
Yes Yes No Yes Yes Yes 
33. The answer to the study question is given. Yes Yes Yes Yes Yes Yes 
34. Conclusions follow from the data reported. Yes Yes Yes Yes Yes Yes 
35. Conclusions are accompanied by the appropriate caveats. Yes Yes No Yes Yes Yes 
 Luciano et al. 
(in press) 
Ekers et al. 
(2011) 
Richards et 
al. (2016) 
Priebe et al. 
(2012) 
Lengacher et 
al. (2015) 
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Study design       
1. The research question is stated. Yes N.C. Yes Yes Yes  
2. The economic importance of the research question is stated. Yes No Yes Yes Yes  
3. The viewpoint(s) of the analysis are clearly stated and justified. Yes Yes Yes Yes Yes  
Selection of alternatives       
4. The rationale for choosing alternative programmes or interventions 
compared is stated. 
Yes N.C. Yes Yes No 
 
5. The alternatives being compared are clearly described.  Yes No Yes Yes Yes  
Form of evaluation       
6. The form of economic evaluation used is stated. Yes Yes Yes Yes Yes  
7. The choice of form of economic evaluation is justified in relation to the 
questions addressed. 
Yes Yes Yes Yes Yes 
 
Effectiveness data       
8. The source(s) of effectiveness estimates used are stated. Yes Yes Yes Yes Yes  
9. Details of the design and results of effectiveness study are given (if based on 
a single study). 
Yes N.C. Yes Yes No 
 
10. Details of the methods of synthesis or meta-analysis of estimates are given 
(if based on a synthesis of a number of effectiveness studies). 
N.A. N.A. N.A. N.A. N.A. 
 
Benefit measurement and valuation       
11. The primary outcome measure(s) for the economic evaluation are clearly 
stated. 
Yes Yes Yes Yes Yes 
 
12. Methods to value benefits are stated. Yes N.C. Yes Yes Yes  
13. Details of the subjects from whom valuations were obtained were given. Yes No Yes Yes Yes  
14. Productivity changes (if included) are reported separately. Yes N.A. Yes Yes N.A.  
15. The relevance of productivity changes to the study question is discussed. No N.A. N.C. No N.A.  
Costing       
16. Quantities of resource use are reported separately from their unit costs. No No No Yes No  
17. Methods for the estimation of quantities and unit costs are described. Yes Yes N.C. N.C. Yes  
18. Currency and price date are recorded. Yes Yes Yes Yes No  
19. Details of currency of price adjustments for inflation or currency conversion 
are given. 
Yes No No No N.A. 
 
Modelling       
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20. Details of any model used are given. N.A. N.A. N.A. N.A. N.A  
21. The choice of model used and the key parameters on which it is based are 
justified. 
N.A. N.A. N.A. N.A. N.A 
 
Adjustments timing of costs & benefits       
22. Time horizon of costs and benefits is stated. Yes Yes Yes Yes Yes  
23. The discount rate(s) is stated. N.A. N.A. Yes N.A. Yes  
24. The choice of discount rate(s) is justified. N.A. N.A. Yes N.A. Yes  
25. An explanation is given if costs and benefits are not discounted. N.A. N.A. N.A N.A. N.A.  
Allowance for uncertainty       
26. Details of statistical tests and confidence intervals are given for stochastic 
data. 
Yes Yes Yes Yes Yes 
 
27. The approach to sensitivity analysis is given. Yes N.A. Yes No Yes  
28. The choice of variables for sensitivity analysis is justified. No N.A. Yes No Yes  
29. The ranges over which the variables are varied are justified. No N.A. Yes. No Yes  
30. Relevant alternatives are compared. Yes Yes Yes No Yes  
Presentation of results       
31. Incremental analysis is reported. Yes Yes Yes Yes Yes  
32. Major outcomes are presented in a disaggregated as well as aggregated 
form. 
Yes No Yes Yes No 
 
33. The answer to the study question is given. Yes Yes Yes Yes Yes  
34. Conclusions follow from the data reported. Yes Yes Yes Yes Yes  
35. Conclusions are accompanied by the appropriate caveats. Yes Yes Yes Yes No  
N.A., Not applicable. 
N.C., Not clear 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
flow diagram from record identification to study inclusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through database searching 
(n= 1339) 
 
PUBMED/MEDLINE (n= 381) 
EMBASE (n= 505) 
CINAHL (n= 159) 
PsycINFO (n= 294) 
Additional records identified through 
other electronic databases (Cochrane 
Library and Google Scholar) (n= 2) and 
contacting experts in the field (n= 1) 
Records after duplicates removed (n= 765) 
Records screened by title and Abstract (n= 765) Records excluded (n= 730) 
Full-text articles assessed for 
eligibility (n= 35) 
Full-text articles excluded, with 
reasons (n= 24): 
 
- Study protocol (n= 10) 
- No economic evaluation (n= 5) 
- Systematic review (n= 6) 
- Methodological paper (n= 1) 
- Multicomponent program (n= 1) 
- Uncontrolled study (n= 1)  
 
 Studies included in qualitative 
synthesis (n= 11) 
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Figure 2. Risk of bias assessment for each included study using the Cochrane Collaboration’s tool for assessing risk of bias (Higgins et al., 
2011) 
Key: + indicates low risk of bias, − indicates high risk of bias, and ? indicates unclear risk of bias. 
K
u
y
k
en
 et a
l. 
(2
0
0
8
) 
v
an
 
R
av
esteijn
 et 
a
l. (2
0
1
3
) 
B
o
g
o
sian
 et 
a
l. (2
0
1
5
) 
K
u
y
k
en
 et a
l. 
(2
0
1
5
) 
S
h
aw
y
er et 
a
l. (2
0
1
6
) 
K
em
an
i et a
l. 
(2
0
1
5
) 
L
u
cian
o
 et a
l. 
(2
0
1
6
) 
E
k
ers et a
l. 
(2
0
11
a) 
R
ich
ard
s et 
a
l. (2
0
1
6
) 
P
rieb
e et a
l. 
(2
0
1
2
) 
L
en
g
ach
er et 
a
l. (2
0
1
5
) 
 
           Random sequence generation 
(selection bias) 
  
 
 
    
   Allocation concealment 
(selection bias) 
     
 
  
 
 
 Blinding 
(performance bias and detection bias) 
           Incomplete outcome data 
(attrition bias) 
           
Selective reporting 
(reporting bias) 
            
Other bias 
 
 
+ 
- 
+ 
+ 
? 
? 
+ 
- 
+ 
+ 
- 
+ 
+ 
+ 
+ 
? ? 
- 
+ 
+ 
+ 
- - 
+ 
+ 
+ 
+ 
- - 
+ 
+ 
- 
? 
? 
+ 
? 
- 
+ 
- 
? 
+ 
+ 
- 
+ 
- 
- 
? 
- 
+ 
+ 
- 
+ 
? ? 
+ 
- 
? 
+ 
+ ? 
+ 
+ 
- 
+ 
+ 
? 
RUNNING HEAD: ECONOMIC EVALUATION OF THIRD-WAVE CBT 52 
 
 
 
Other bias: 
Kuyken et al (2008, 2015). The antidepressant medication was not fully controlled. 
van Ravesteijn et al (2013). The authors did not systematically evaluate the treatment integrity and therapist competency. They did not keep a record of their compliance with the patients’ 
homework exercises. 
Bogosian et al (2015). One of the authors notified participants of their group allocation and was the mindfulness instructor that delivered all the mindfulness courses. 
Kemani et al (2015). High amount of missing economic data. Therapists in the ACT condition were more familiar with the treatment method. 
Luciano et al (in press). The authors cannot dismiss the possibility that patients from the GACT condition concealed the use of medications, for example the use of opioids or anxiolytics as 
rescue medication. In contrast, participants in the RPT can claim to have taken their prescribed medication, when this is not the case. 
Ekers et al (2011). Lack of follow-up and small sample size (underpowered RCT). Quality of behavioural activation administered was not measured. 
Richards et al (2016). Missing data for the primary outcome measure was substantial. 
Priebe et al (2012). RCT carried out in a relatively small sample size (underpowered RCT). One of the coauthors evaluated the adherence to DBT. The authors assessed indirect costs caused by 
sickness absence exclusively 
Lengacher et al (2015). It is unclear whether more than one MBSR instructor delivered the MBSR program. The original MBSR program was modified to a 6-week format and excluded the 
recommended one-day retreat. 
 
 
